Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMPION-MTX methotrexate withdrawal strategies in nonsystemic juvenile idiopathic arthritis
ACTRN12626000411347Phase 4Recruiting
- Sponsor
- University of Sydney
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by University of Sydney. Primary endpoint: JIA flare rate. Started Sep 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on ACTRN12626000411347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000411347.